ACCESS Newswire
25 Jan 2023, 00:13 GMT+10
NEW YORK, NY / ACCESSWIRE / January 24, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
NEO Shareholders Click Here: https://www.zlk.com/pslra-1/neogenomics-lawsuit-submission-form?prid=35898&wire=1
AVYA Shareholders Click Here: https://www.zlk.com/pslra-1/avaya-holdings-loss-submission-form?prid=35898&wire=1
YMAB Shareholders Click Here: https://www.zlk.com/pslra-1/y-mabs-therapeutics-loss-submission-form?prid=35898&wire=1
* ADDITIONAL INFORMATION BELOW *
NEO Lawsuit on behalf of: investors who purchased February 27, 2020 - April 26, 2022
Lead Plaintiff Deadline : February 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/neogenomics-lawsuit-submission-form?prid=35898&wire=1
According to the filed complaint, during the class period, NeoGenomics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) defendants represented to investors that it had a 'comprehensive menu' of cancer tests with 'every kind of testing modality that you can use for cancer, including some of the fast-growing new ones, like next-generation sequencing,' which positioned the Company as a 'one-stop-shop' for pathologists and gave NeoGenomics 'a competitive advantage' as a 'go-to reference lab with a comprehensive menu for just about any kind of tests that you want to have done in cancer' and (2) defendants represented that NeoGenomics could 'leverage' the supposedly 'fixed cost' structure of its business to improve profitability as revenue increased and touted the Company's 'robust Compliance Program . . . to ensure compliance with the myriad of . . . laws, regulations and governmental guidance applicable to our business.'
AVYA Lawsuit on behalf of: investors who purchased November 22, 2021 - November 29, 2022
Lead Plaintiff Deadline : March 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/avaya-holdings-loss-submission-form?prid=35898&wire=1
According to the filed complaint, during the class period, Avaya Holdings Corp. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's internal control over financial reporting was deficient in several areas; (ii) as a result of these deficiencies, the Company had failed to design and maintain effective controls over its whistleblower policies and its ethics and compliance program; (iii) the Company's deteriorating financial condition was likely to raise substantial doubt as to its ability to continue as a going concern; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
This lawsuit is on behalf of persons or entities who purchased shares of Y-mAbs Therapeutics, Inc. common stock on the open market or pursuant to registration statements filed with the U.S. Securities and Exchange Commission during the period October 6, 2020 through October 28, 2022, inclusive.
Lead Plaintiff Deadline : March 20, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/y-mabs-therapeutics-loss-submission-form?prid=35898&wire=1
According to the filed complaint, (i) Y-mAbs misrepresented the U.S. Food and Drug Administration's ('FDA') willingness to approve omburtamab, the Company's lead product candidate, for marketing based on the existing clinical trials; (ii) the Company misrepresented that progress was being made that would align with the FDA's requirements to demonstrate substantial evidence of effectiveness, sufficient for approval of omburtamab, through adequate and well-controlled studies; (iii) the FDA had repeatedly advised Y-mAbs that it was unlikely to grant approval for the marketing of omburtamab; and (iv) Y-mAbs had elected to submit the March 31, 2022 Biologics License Application prior to reaching agreement with the FDA on the content of the application.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
Get a daily dose of Raleigh Times news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Raleigh Times.
More InformationNEW YORK, New York -U.S. stock markets closed with broad gains on Thursday, led by strong performances in U.S. tech stocks, while European...
LONDON/STOCKHOLM: The Persson family is ramping up its investment in the H&M fashion empire, fueling renewed speculation about a potential...
PARIS, France: L'Oréal is making a fresh play in the booming premium haircare segment with a new acquisition. The French beauty conglomerate...
MENLO PARK, California: Robinhood is giving European investors a new way to tap into America's most prominent tech names — without...
NEW YORK, New York - U.S. stocks diverged on Wednesday for the second day in a row. The Standard and Poor's 500 hit a new all-time...
NEW YORK CITY, New York: The U.S. dollar continues to lose ground, weighed down by growing concerns over Washington's fiscal outlook...
WASHINGTON, D.C.: In a significant ruling last week, the U.S. Supreme Court upheld a Texas law requiring age verification for users...
The U.S. mega-bill would add about 3.3 trillion dollars of deficit in the next decade, higher than the 2.8 trillion dollars of deficit...
Washington [US], July 1 (ANI): US President Donald Trump on Tuesday (local time) reiterated his opposition to electric vehicle (EV)...
Birmingham [UK], July 1 (ANI): Ahead of England's second Test against India at Birmingham, England skipper Ben Stokes spoke on express...
Washington [US], June 30 (ANI): Tech billionaire Elon Musk strongly criticised President Trump's 'big, beautiful bill,' calling it...
GOP leaders are determined to advance Trump's signature agenda. But the bill's complexity, internal party fractures and Democratic...